Enterprise Financial Services Corp Biomarin Pharmaceutical Inc Transaction History

Enterprise Financial Services Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 13, 2021	SELL	$74.73 - $90.69 $747 - $906	-10 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$72.61 - $90.2 $726 - $902	10 New	10 $1,000
Q2 2020 Aug 04, 2020	SELL	$79.55 - $124.22 $1,431 - $2,235	-18 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$71.37 - $96.85 $1,284 - $1,743	18 New	18 $2,000
Q3 2019 Oct 31, 2019	SELL	$67.4 - $85.11 $1,685 - $2,127	-25 Closed	0 $0
Q2 2019 Jul 30, 2019	SELL	$80.35 - $93.9 $1,526 - $1,784	-19 Reduced 43.18%	25 $2,000
Q1 2019 Apr 26, 2019	BUY	$84.2 - $98.62 $1,599 - $1,873	19 Added 76.0%	44 $4,000
Q4 2018 Jan 25, 2019	SELL	$80.14 - $106.07 $3,045 - $4,030	-38 Reduced 60.32%	25 $2,000
Q3 2018 Oct 26, 2018	BUY	$93.92 - $105.72 $3,568 - $4,017	38 Added 152.0%	63 $6,000
Q2 2018 Jul 27, 2018	SELL	$76.01 - $99.03 $2,432 - $3,168	-32 Reduced 56.14%	25 $2,000
Q3 2017 Oct 27, 2017	BUY	$80.6 - $94.95 $4,594 - $5,412	57	57 $5,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Enterprise Financial Services Corp, based on Form 13F filings with the SEC.

Stay updated on Enterprise Financial Services Corp with notifications on news.